Free Trial
NASDAQ:PCRX

Pacira BioSciences Q2 2025 Earnings Report

Pacira BioSciences logo
$22.07 +0.98 (+4.65%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$22.07 0.00 (0.00%)
As of 08/1/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira BioSciences EPS Results

Actual EPS
N/A
Consensus EPS
$0.73
Beat/Miss
N/A
One Year Ago EPS
N/A

Pacira BioSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$183.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pacira BioSciences Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Pacira BioSciences Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Pacira BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email.

About Pacira BioSciences

Pacira BioSciences (NASDAQ:PCRX) is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

View Pacira BioSciences Profile

More Earnings Resources from MarketBeat